AASLD 2020 – Nash updates from Novo and Inventiva in focus
At the US liver conference Inventiva will make a case for PPAR agonism, while Novo Nordisk and Gilead’s combo will be scrutinised in Nash.
Novo adds weight to its obesity goals
Analysts see semaglutide helping Novo Nordisk to beat its sales target in obesity, but the company has bigger ambitions for earlier projects.
The Cymabay recovery continues
Encouraging cholangitis data follows the lifting of a clinical hold on Cymabay’s seladelpar, signalling a way forward for a project that looked finished.
Galapagos finds little comfort in safety
Filgotinib’s mixed efficacy in ulcerative colitis prompts a shares slide.
Genfit’s predictable liver disease failure sets up a cirrhosis pivot
Five years after failing phase II in Nash, elafibranor fails phase III in Nash; a focus on liver cirrhosis beckons.
Roche’s test of novel gut target nears
Pivotal ulcerative colitis data on etrolizumab, a dual-action anti-integrin antibody, are due soon, and Roche has Takeda’s Entyvio in its sights.
